特利加压素在肝癌合并肝肾综合征患者介入治疗中的应用

Evaluation of Terlipressin in Treating Patients with Hepatic Carcinoma Complicated by Hepatorenal Syndrome

目的探讨特利加压素在肝癌合并肝肾综合征(HRS)患者介入治疗中的应用。方法搜集18例肝癌合并HRS且使用过特利加压素治疗的患者临床资料,对比其治疗前后的血清肌酐、血尿素氮、血清钠、24小时尿量变化。结果 18例患者经以特利加压素为基础的综合治疗,治疗后尿量、血清肌酐,血尿素氮、血清钠较治疗前明显好转(P<0.05)。肾功能逐渐改善,治疗有效率达100%。2例患者在肾功能恢复正常停用特利加压素后的第2及第3天出现无尿症状而死亡。结论对肝癌合并HRS的患者,早期采用特利加压素为基础的综合治疗是安全和有效的。

Objective To investigate the application of terlipressin in treating patients with hepatic carcinoma complicated by hepatorenal syndrome.Methods A total of 18 patients with hepatic carcinoma associated with hepatorenal syndrome,who had received terlipressin treatment,were collected.The clinical data,including pre-treatment and post-treatment serum creatinine,blood urea nitrogen,serum sodium and urine output of 24 hours,were determined and the results were compared.Results After terlipressin-based treatment,the serum creatinine level,blood urea nitrogen,serum sodium and urine output of 24 hours were significantly improved in all 18 patients（ P 〈 0.05）.The renal function was gradually improved,and the effective rate of treatment was 100%.Two patients died of anuria at 2 and 3 days respectively after renal function was recovered and the use of terlipressin was stopped.Conclusion For the treatment of hepatic carcinoma complicated by hepatorenal syndrome,early use of terlipressin-based comprehensive treatment is safe and effective.